Pharmacogenetic Aspect of Intravitreal Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Five-Year Follow-Up

Şengül, Elvan Alper; Artunay, Özgür; Rasier, Rıfat; Koçkar, Alev; Afacan, Ceyda; Hancer, Veysel Sabri; Yüzbaşıoğlu, Erdal

doi:10.1080/09273948.2017.1311925

Cited by 4 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numerous studies have indicated that NLR and PLR are markers of increased systemic inflammation. [11][12][13][14][15][16][17][18][19] One study associated a high NLR with a poor prognosis in trauma patients, particularly those with traumatic brain injury. [25] High NLR and PLR have also been linked to poor outcomes in various diseases.…”

Section: Discussionmentioning

confidence: 99%

“…[11][12][13] It has been observed that these ratios increase in various eye diseases and are correlated with the severity of the condition. [14][15][16][17][18][19] A study focusing on adult populations with OGI found that high baseline NLR and PLR values were associated with a worse prognosis. [20] Our study aims to evaluate pediatric patients with OGI using the MPOTS and to investigate the impact of NLR and PLR parameters on prognosis and MPOTS scores.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluating the effectiveness of inflammatory markers in pediatric open globe injury using a modified pediatric ocular trauma score

Özcanlı Çay

2024

Ulus Travma Acil Cerrahi Derg

View full text Add to dashboard Cite

BACKGROUND: This study aims to assess pediatric patients with Open Globe Injury (OGI) using the Modified Pediatric Ocular Trauma Score (MPOTS) and to investigate the correlation between Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) parameters with the prognosis determined by MPOTS. METHODS: In this retrospective study, we included pediatric patients with OGI. Recorded data encompassed demographic details, injury type, duration from injury to surgery, complete ophthalmological examinations, initial and final visual acuities, anterior segment and fundus findings, and NLR and PLR values. Patients were categorized into three groups based on their MPOTS scores: Grade I (≤30 points), indicating high risk; Grade II (35-65 points), moderate risk; and Grade III (≥70 points), low risk. Differences between categories were statistically evaluated. RESULTS: The study comprised 22 patients. In Category I, the duration from injury to surgery was longer (p=0.018). The most common injury type in this category was globe rupture, occurring in four (50%) patients, with a significant difference noted between the groups (p=0.041). Category I exhibited lower final visual acuity and higher NLR and PLR values compared to the other categories (p<0.050 for all values). Both NLR and PLR demonstrated significant negative correlations with MPOTS (respectively, r=-0.869, p<0.001; r=-0.809, p<0.001). CONCLUSION: The Modified Pediatric Ocular Trauma Score is an effective and practical method for assessing the prognosis of pediatric patients with Open Globe Injury (OGI). Furthermore, there is evidence indicating a negative correlation between MPOTS and the increase in NLR and PLR values that often follows OGI in this patient population.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Evaluating the effectiveness of inflammatory markers in pediatric open globe injury using a modified pediatric ocular trauma score

Özcanlı Çay

2024

Ulus Travma Acil Cerrahi Derg

View full text Add to dashboard Cite

show abstract

“…However, the underlying mechanism of refractility to treatment is not fully understood and management of these patients is often limited to switching of different anti-VEGFs [49]. Interestingly, several association studies have indicated a role of complement polymorphism in anti-VEGF treatment response (CFH CC genotype), although results are not con rmative and long-term follow up is limited [50,51].…”

Section: Introductionmentioning

confidence: 99%

Preclinical development of a dual targeting bicistronic gene therapy approach for the treatment of wet age-related macular degeneration

Tam,

Joel,

Stampoulis

et al. 2024

Preprint

View full text Add to dashboard Cite

Age-related macular degeneration (AMD) continues to be a leading cause of severe vision impairment affecting millions worldwide. The late stages of AMD are characterized by outer retinal atrophy (geographic atrophy, GA), or neovascularization associated with subretinal and/or intraretinal exudation (exudative neovascular or ‘wet’ AMD). Intravitreal (IVT) administration of anti-vascular endothelial growth factor (VEGF) therapies has dramatically improved vision preservation for wet AMD (wAMD) patients. However, current Standard of Care (SoC) has significant shortcomings and the benefits of anti-VEGF therapy in the real-world setting fall short of the vision gains observed in randomized clinical trials. This is thought to be attributable to drug burden to patients, lack of therapeutic durability due to progression of underlying macular atrophy and refractility to treatment. Vectorized anti-VEGF therapy has been shown to be effective in reducing drug burden clinically but is unlikely to address the progression of the underlying GA driven by complement-mediated inflammation. Here, we aim to address this unmet need by developing a bicistronic gene therapy vector co-expressing aflibercept and Factor H-like protein 1 (FHL-1) to target the pro-angiogenic and pro-inflammatory environment of wAMD. In vitro assays confirmed the anti-angiogenic and complement inhibitory properties of the bicistronic vector. Recombinant AAV8 (rAAV8)-mediated co-expression was detected for up to 4 weeks following subretinal delivery in wild type (WT) mice. In a mouse laser-induced choroidal neovascularization (CNV) model, subretinal delivery of bicistronic vectors significantly reduced both CNV leakage and lesion. These results demonstrate that a single subretinal administration of bicistronic vector may provide an effective treatment option for wAMD and may also prolong patient’s visual outcomes by preventing the underlying progression of GA.

show abstract

Pharmacogenomics of Biologics

Ward¹

2020

Biologics, Biosimilars, and Biobetters

View full text Add to dashboard Cite

Pharmacogenetic Aspect of Intravitreal Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Five-Year Follow-Up

Abstract: Patients with CFH TT genotype responded significantly better to treatment after third year, while patients with CC genotype had a poorer response to IVR.

Cited by 4 publications

References 20 publications

Evaluating the effectiveness of inflammatory markers in pediatric open globe injury using a modified pediatric ocular trauma score

Evaluating the effectiveness of inflammatory markers in pediatric open globe injury using a modified pediatric ocular trauma score

Preclinical development of a dual targeting bicistronic gene therapy approach for the treatment of wet age-related macular degeneration

Pharmacogenomics of Biologics

Contact Info

Product

Resources

About